Zdrowie i gospodarka · 27/09/2018

FDA Announces Fee Rate for Rare Pediatric Disease Priority Review Voucher for Fiscal Year 2019

The US Food and Drug Administration (FDA) has set the fee rate for using a rare pediatric disease priority review voucher for fiscal year 2019, based on the average cost of reviewing human drug applications designated as priority review in the previous year.